Pendal Group LTD Qiagen N.V. Transaction History

Pendal Group LTD

$12.2 Billion
Q4 2022

A detailed history of Pendal Group LTD transactions in Qiagen N.V. stock. As of the latest transaction made, Pendal Group LTD holds 4,302,433 shares of QGEN stock, worth $213 Million. This represents 1.76% of its overall portfolio holdings.

Number of Shares

4,302,433

Previous 5,258,339 18.18%

Holding current value

$213 Million

Previous $217 Million 1.13%

% of portfolio

1.76%

Previous 2.11%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 19, 2023	SELL	$41.91 - $50.48 $40.1 Million - $48.3 Million	-955,906 Reduced 18.18%	4,302,433 $0
Q3 2022 Oct 18, 2022	BUY	$40.9 - $50.42 $83.8 Million - $103 Million	2,049,960 Added 63.89%	5,258,339 $217 Million
Q2 2022 Jul 25, 2022	BUY	$42.98 - $49.77 $120 Million - $139 Million	2,799,528 Added 684.73%	3,208,379 $151 Million
Q1 2022 Apr 25, 2022	BUY	$42.23 - $54.3 $33,952 - $43,657	804 Added 0.2%	408,851 $20 Million
Q4 2021 Jan 18, 2022	BUY	$50.62 - $56.47 $6.67 Million - $7.44 Million	131,781 Added 47.7%	408,047 $22.7 Million
Q3 2021 Nov 05, 2021	BUY	$46.55 - $56.83 $876,955 - $1.07 Million	18,839 Added 7.32%	276,266 $14.3 Million
Q2 2021 Jul 28, 2021	BUY	$46.28 - $52.75 $2.71 Million - $3.08 Million	58,472 Added 29.39%	257,427 $12.5 Million
Q1 2021 May 24, 2021	BUY	$46.25 - $56.02 $9.2 Million - $11.1 Million	198,955 New	198,955 $9.69 Million
Q1 2021 May 03, 2021	SELL	$46.25 - $56.02 $3.08 Million - $3.73 Million	-66,527 Closed	0 $0
Q4 2020 Jan 21, 2021	BUY	$46.09 - $54.74 $3.07 Million - $3.64 Million	66,527 New	66,527 $3.52 Million

Others Institutions Holding QGEN

# of Institutions

Shares Held

5.57M

Call Options Held

Put Options Held

View Full List

About QIAGEN N.V.

Ticker QGEN
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 227,694,000
Market Cap $11.3B
Description
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacteria...

More about QGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pendal Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pendal Group LTD with notifications on news.

Account